Search results summary
From Health Canada
Search criteria
- Status: Select all
- AIG: 0262970001
Search results
Status | DIN | Company | Product | Class | PM See footnote1 | Schedule | # See footnote2 | A.I. name See footnote3 | Strength |
---|---|---|---|---|---|---|---|---|---|
Authorized By Interim Order | 02516691 | HOFFMANN-LA ROCHE LIMITED | CASIRIVIMAB AND IMDEVIMAB | Human | Yes | Prescription | 2 | CASIRIVIMAB | 300 MG / 2.5 ML |
Authorized By Interim Order | 02516691 | HOFFMANN-LA ROCHE LIMITED | CASIRIVIMAB AND IMDEVIMAB | Human | Yes | COVID-19 - IO - Authorization | 2 | CASIRIVIMAB | 300 MG / 2.5 ML |
Authorized By Interim Order | 02516691 | HOFFMANN-LA ROCHE LIMITED | CASIRIVIMAB AND IMDEVIMAB | Human | Yes | Schedule D | 2 | CASIRIVIMAB | 300 MG / 2.5 ML |
Marketed | 02516705 | HOFFMANN-LA ROCHE LIMITED | CASIRIVIMAB AND IMDEVIMAB | Human | Yes | COVID-19 - IO - Authorization | 2 | CASIRIVIMAB | 1332 MG / 11.1 ML |
Marketed | 02516705 | HOFFMANN-LA ROCHE LIMITED | CASIRIVIMAB AND IMDEVIMAB | Human | Yes | Prescription | 2 | CASIRIVIMAB | 1332 MG / 11.1 ML |
Marketed | 02516705 | HOFFMANN-LA ROCHE LIMITED | CASIRIVIMAB AND IMDEVIMAB | Human | Yes | Schedule D | 2 | CASIRIVIMAB | 1332 MG / 11.1 ML |
Application information
Related information
Contact us
Version 4.0.2